Analysts at BMO Capital Markets initiated coverage on shares of Omada Health (NASDAQ:OMDA – Get Free Report) in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $27.00 price target on the stock. BMO Capital Markets’ target price would indicate a potential upside of 26.11% from the stock’s current price.
Several other equities analysts also recently weighed in on the company. Needham & Company LLC lifted their target price on Omada Health from $26.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Robert W. Baird assumed coverage on Omada Health in a research report on Friday, September 5th. They set a “neutral” rating and a $24.00 target price on the stock. Evercore ISI raised their price target on shares of Omada Health from $27.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Omada Health in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group boosted their target price on shares of Omada Health from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $26.33.
View Our Latest Stock Report on OMDA
Omada Health Stock Down 0.2%
Institutional Investors Weigh In On Omada Health
A number of large investors have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in Omada Health in the second quarter worth approximately $32,000. Strs Ohio purchased a new position in Omada Health during the third quarter valued at approximately $38,000. Rakuten Investment Management Inc. bought a new stake in Omada Health during the third quarter worth approximately $49,000. JPMorgan Chase & Co. bought a new position in Omada Health in the third quarter worth approximately $82,000. Finally, Rhumbline Advisers purchased a new stake in Omada Health during the 3rd quarter worth approximately $176,000.
About Omada Health
Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.
Further Reading
- Five stocks we like better than Omada Health
- Short Selling – The Pros and Cons
- Oklo’s Meltdown Is Over: A Robust Rebound Lies Ahead
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 3 Reasons On Holding’s Sell-Off Is Over and New Highs Are Coming
- Investing In Preferred Stock vs. Common Stock
- As Warren Buffett Nears His Exit, Berkshire’s Amassed Record Cash
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
